|
ORF cDNA clones
|
CRISPR / TALEN
|
Lentivirus
|
AAV
|
TALE-TF
|
ORF knockin clones
|
|
Antibody
|
Proteins
|
miRNA target clones
|
qPCR primers
|
shRNA clones
|
miRNA products
|
Promoter clones
|
Validated All-in-One™ qPCR Primer for HLA-DRA(NM_019111.4) Search again
Product ID:
HQP100190
(click here to view gene annotation page)
Powered by BiozSpecies:
Human
Symbol:
Alias:
HLA-DRA1
Gene Description:
major histocompatibility complex, class II, DR alpha
Target Gene Accession:
NM_019111.4(click here to view gene page)
Estimated Delivery:
Approximately 1-3 weeks, but may vary. Please email sales@genecopoeia.com or call 301-762-0888 to confirm ETA.
Important Note:
By default, qPCR primer pairs are designed to measure the expression level of the splice variant (accession number) you selected for this gene WITHOUT consideration of other possible variants of this gene. If this gene has multiple variants, and you would like to measure the expression levels of one particular variant, multiple variants, or all variants, please contact us for a custom service project at inquiry@genecopoeia.com.
Validated result:
|
|
| A | B |
|
Each All-in-One™ qPCR Primer is experimentally validated to yield a single dissociation curve peak and to generate a single amplification of the correct size for the targeted gene. A cDNA Pool, containing reverse transcript products of 8 different human tissue total RNA(Liver, Testis,Muscle,Thyroid,Brain,Spleen,Stomach,Small Intestine)),was used as the qPCR validation template. qPCR was performed using 0.2 µM primer with 2XAll-in-One™ qPCR Mix (Catalog#: QP001,QP002,QP004,QP005). Reactions were incubated for 10min. at 95°C, followed by 40 cycles of 95°C for 10 sec.; 60°C, 20 sec. and 72°C, 15sec. using Bio-Rad iQ5™ Instrument. At the end of the last cycle, temperature was increased from 72 to 95°C to produce a melting curve. Panel A: Validated Result for Amplification Curve; Panel B: Validated Result for Melting Curve. |
|
Summary
HLA-DRA is one of the HLA class II alpha chain paralogues.
Gene References into function
- P. gingivalis membrane vesicles apparently inhibited IFN-gamma-induced MHC class II (HLA-DRalpha) by disrupting the IFN-gamma signaling transduction pathway.
- IFN-gamma-induced HLA-DRA expression was inhibited by nitric oxide (NO) and antioxidants such as superoxide dismutase, catalase, pyrrolidine dithiocarbamate, and N-acetylcysteine
- The donor TNFRSF6 polymorphism dierctly or indirectly influences acute kidney rejection episodes.
- different regions of the cytoplasmic tails are involved in the association and the recruitment of HLA-DR(A & B1) into different compartments. HLA-DP and -DR interact differently with the cytoskeleton.
- Data show that Oct-1 occupies the endogenous HLA-DRA promoter when the HLA-DRA promoter is inactive in retinoblastoma protein-defective cells.
- Overexpression of HLA-DRA is associated with ovarian and other cancers
- Downregulation of HLA-DRA is associated with early intrahepatic recurrence of hepatocellular carcinoma
- Alleles of IL2RA and IL7RA and those in the HLA locus are identified as heritable risk factors for multiple sclerosis.
- frequency of HLA antigens was significantly increased suggesting that brain cavernoma susceptibility may be associated with HLA antigens
- HLA-DR alpha 2 domain (sHLA-DRalpha2) induces negative signals by engaging TIRC7 on lymphocytes, inhibiting proliferation and inducing apoptosis in CD4+ and CD8+ T-cells via activation of the intrinsic pathway